Furthermore, STAT3 activation in epithelial cells is dependent on IL-22 rather than IL-6 (94), suggesting that targeting the STAT3 signaling pathway in intestinal epithelial cells (IECs) is a promising therapeutic approach for IBD patients (95). The gene discussed is IL22; the disease is inflammatory bowel disease.